Lacutamab is a monoclonal antibody commercialized by Innate Pharma, with a leading Phase II program in Natural Killer Cell Lymphomas. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Lacutamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lacutamab is expected to reach an annual total of $62 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Lacutamab (IPH-4102) is under development for the treatment of relapsed and refractory sezary syndrome (SS),cutaneous T-cell lymphomas such as transformed mycosis fungoides (TMF),and relapsed and refractory including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, adult T-cell leukemia/lymphoma (ATL), hepatosplenic T-cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and aggressive NK-cell leukemia (ANKL). It was administered intravenously. The drug candidate is a cytotoxic antibody against KIR3DL2-expressing cancers.
Innate Pharma Overview
Innate Pharma is a biotechnology company that develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL); Monalizumab, an immune checkpoint inhibitor targeting solid tumors, head and neck cancer, and Avdoralimab antibody against bullous pemphigoid. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.
The company reported revenues of (Euro) EUR12.1 million for the fiscal year ended December 2021 (FY2021), a decrease of 78.4% over FY2020. The operating loss of the company was EUR47.8 million in FY2021, compared to an operating profit of EUR1.1 million in FY2020. The net loss of the company was EUR52.8 million in FY2021, compared to a net loss of EUR64 million in FY2020.
For a complete picture of Lacutamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.